Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Romain-David SebanAntoine Moya-PlanaLara AntoniosRandy YehAurélien MarabelleEric DeutschLawrence H SchwartzRuth Gabriela Herrera GómezYvonne SaengerCaroline RobertSamy AmmariLaurent DerclePublished in: European journal of nuclear medicine and molecular imaging (2020)
While all Muc-M and Cut-M were FDG avid, prognostic imaging biomarkers differed. For Muc-M patients treated with ICI, the only prognostic imaging biomarker was a high baseline maximal glycolytic activity (SUVmax), whereas for Cut-M patients, baseline metabolic tumor burden or bone marrow metabolism was negatively correlated to ICI response duration.
Keyphrases
- pet ct
- bone marrow
- positron emission tomography
- pet imaging
- high resolution
- end stage renal disease
- newly diagnosed
- ejection fraction
- small cell lung cancer
- mesenchymal stem cells
- computed tomography
- chronic kidney disease
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- risk factors
- cancer therapy
- patient reported outcomes
- photodynamic therapy
- ulcerative colitis